NASDAQ: MRNS

Marinus Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

The consensus among 6 Wall Street analysts covering (NASDAQ: MRNS) stock is to Buy MRNS stock.

Out of 6 analysts, 2 (33.33%) are recommending MRNS as a Strong Buy, 1 (16.67%) are recommending MRNS as a Buy, 3 (50%) are recommending MRNS as a Hold, 0 (0%) are recommending MRNS as a Sell, and 0 (0%) are recommending MRNS as a Strong Sell.

If you're new to stock investing, here's how to buy Marinus Pharmaceuticals stock.

(NASDAQ: MRNS) Marinus Pharmaceuticals's forecast annual revenue growth rate of 70.93% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.92%.

Marinus Pharmaceuticals's revenue in 2024 is $30,989,000.On average, 5 Wall Street analysts forecast MRNS's revenue for 2024 to be $2,182,096,790, with the lowest MRNS revenue forecast at $1,815,226,508, and the highest MRNS revenue forecast at $2,710,271,968. On average, 5 Wall Street analysts forecast MRNS's revenue for 2025 to be $3,775,692,993, with the lowest MRNS revenue forecast at $2,447,987,584, and the highest MRNS revenue forecast at $6,977,857,466.

In 2026, MRNS is forecast to generate $9,484,695,109 in revenue, with the lowest revenue forecast at $7,184,023,920 and the highest revenue forecast at $13,789,601,489.

According to 6 Wall Street analysts that have issued a 1 year MRNS price target, the average MRNS price target is $13.17, with the highest MRNS stock price forecast at $28.00 and the lowest MRNS stock price forecast at $2.00.

On average, Wall Street analysts predict that Marinus Pharmaceuticals's share price could reach $13.17 by Apr 17, 2025. The average Marinus Pharmaceuticals stock price prediction forecasts a potential upside of 827.25% from the current MRNS share price of $1.42.

(NASDAQ: MRNS) forecast ROE is N/A, which is considered weak.